secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001493152-24-032926
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate increases ATM offering capacity by $2.86M; receives European patent for ADHD drug CTx-1301
--------------------------------------------------------------------------------

- Increased maximum aggregate offering of common stock under Sales Agreement from $8.47M to $11.33M; filed prospectus supplement for $2.86M in additional shares.
- Previously sold $8.47M of common stock under the Sales Agreement with H.C. Wainwright & Co.
- European patent (EP 3261625) granted for lead asset CTx-1301 (dexmethylphenidate) for ADHD on August 14, 2024.
- Patent covers up to 30 European territories, including the United Kingdom.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224032926/0001493152-24-032926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224032926/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer